Matthew Meyerson

Matthew Meyerson has been a milestone figure in cancer genome characterization, leading systematic efforts that discovered the EML4-ALK fusion and other actionable oncogenic drivers in lung and other cancers, directly translating cancer genome evolution knowledge into clinically approved targeted therapies that have transformed patient outcomes. His work at Dana-Farber and the Broad Institute established the paradigm that comprehensive genomic characterization of tumors can identify evolutionary driver events that serve as therapeutic targets, creating the scientific foundation for genomic cancer medicine. His discoveries exemplify the translation of cancer evolution understanding into clinical benefit.